Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Lifestyle interventions effective against nonobese NAFLD patients

5 days ago

Lifestyle interventions appear to effectively induce remission of nonalcoholic fatty liver disease (NAFLD) in both obese and nonobese patients, reports a new study.

The study included 154 NAFLD patients who were randomly assigned to receive usual care (n=77) or a 12-month lifestyle intervention programme and regular exercise (n=77). In each group, 39 and 38 patients had body mass index (BMI) <25 and 25 kg/m2, respectively. Proton-magnetic resonance spectroscopy was used to assess the primary outcome of NAFLD remission.

Significantly more patients with BMI <25 kg/m2 who received the intervention vs usual care had NAFLD remission at 12 months (67 percent vs 18 percent; p<0.001). In the respective groups, the mean decline in intrahepatic triglyceride content (IHTG) was 6.1 percent and 1.3 percent, the difference between which was statistically significant (p=0.001).

In patients with BMI 25 kg/m2, 61 percent of those who received the lifestyle intervention programme achieved NAFLD remission. This effect was significantly greater than that from usual care (21 percent; p<0.001). The resulting mean reductions in IHTG were 7.4 percent and 2.9 percent, respectively (p=0.004).

The effects of lifestyle intervention also appeared sustainable. A the 6-year follow-up, significantly more participants who received the exercise intervention vs controls had BMI lower than baseline (19.1 percent vs 8.6 percent; p=0.037).

Moreover, although rebound in body weight was observed after termination of the intervention, the mean change in body weight at year 6 was significantly more pronounced in the intervention vs control group (–1.9±4.7 vs 0.4±3.3 kg; p=0.0022).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.